Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Should Pharma Release IP For COVID-19 Research? Novartis Exec Weighs In

Executive Summary

As World Health Assembly prepares resolution for voluntary pooling and licensing, Novartis global head of IP Corey Salsberg discusses how intellectual property is advancing development of therapeutics and vaccines and the benefits of voluntary rather than compulsory licensing; 

You may also be interested in...



EU Politicians Call For Compulsory Licensing, More Joint Procurement For COVID-19

A resolution adopted by the EU’s legislative body includes ways of making Europe more resilient to future pandemics and supply chain risks, and ensuring equitable access to affordable vaccines and medicines. Proposals from the European Parliament to share IP and knowledge have been welcomed by medicines access campaigners.

Global Response To COVID-19 Promises Equitable Access, Independent WHO Probe

A resolution at the latest World Health Assembly meeting on providing universal and equitable access to COVID-19 technologies, medicines and vaccines has been adopted, along with an agreement to review the World Health Organization’s response to the crisis.

Global Response To COVID-19 Promises Equitable Access, Independent WHO Probe

A resolution at the latest World Health Assembly meeting on providing universal and equitable access to COVID-19 technologies, medicines and vaccines has been adopted, along with an agreement to review the World Health Organization’s response to the crisis.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel